|Abstract:||The most common drugs currently in use that may cause myopathies were reviewed using the Medline database (U.S. National Library of Medicine, Bethesda, Maryland). Our review included results from epidemiologic and database surveys, clinical trials, and case reports. The clinical spectrum is wide, and presentations range from asymptomatic elevations in serum creatine phosphokinase levels to severe life-threatening rhabdomyolysis. Management of suspected drug-induced myopathy should include immediate discontinuation of the offending agent, as well as supportive care when needed. Earlier diagnosis and drug discontinuation raises the likelihood of resolution and recovery.|
(Complications and side effects)
Muscle diseases (Risk factors)
Muscle diseases (Diagnosis)
Muscle diseases (Research)
Muscle diseases (Care and treatment)
Protein kinases (Physiological aspects)
Protein kinases (Research)
Mitnick, Hal J.
Pillinger, Michael H.
Wortmann, Robert L.
|Publication:||Name: Bulletin of the NYU Hospital for Joint Diseases Publisher: J. Michael Ryan Publishing Co. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2009 J. Michael Ryan Publishing Co. ISSN: 1936-9719|
|Issue:||Date: Oct, 2009 Source Volume: 67 Source Issue: 4|
|Topic:||Event Code: 310 Science & research|
|Product:||Product Code: 2830000 Drugs & Pharmaceuticals; 2834000 Pharmaceutical Preparations; 2834190 Metabolic Agents; 2834199 Metabolic Agents NEC NAICS Code: 3254 Pharmaceutical and Medicine Manufacturing; 325412 Pharmaceutical Preparation Manufacturing SIC Code: 2834 Pharmaceutical preparations|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
Many drugs can cause myopathies, either predictably or as an
intermittent phenomenon. Clinically, drug-induced myopathies range from
benign processes that cause asymptomatic elevations in serum creatine
phosphokinase (CK) levels (asymptomatic hyper-CK-emia) to mild-to-severe
myalgias, cramps, exercise intolerance, or various degrees of muscle
weakness. Severe cases may result in rhabdomyolysis, with myoglobinuria
that can result in renal failure and even death (Table 1). Diagnosing
drug-induced myopathy can be challenging, particularly as individual
drugs may have different clinical presentations in different patients.
Clinicians turning to the literature will frequently encounter
confusion, in part, because the terminology used to describe muscle
toxicity has been both evolving and, in some cases, imprecise. In this
article, we examine commonly-used drugs that may induce myopathies and
review their clinical syndromes, diagnosis, and treatment. We
particularly focus on newer agents that have been recently described.
Potential mechanisms for myopathies associated with specific drugs are
Materials and Methods
A Medline (U.S. National Library of Medicine, Bethesda, Maryland) search was performed of all English-language published studies from 1980 to 2008 describing drug-induced myopathies; keywords employed are listed in Table 2. Additional references needed to provide background information were also collected. All articles were evaluated for significance and relevance. Those articles found to contain redundant information were excluded.
The Medline search identified 264 articles of potential relevance. Of these, 162 were appropriate to our objective and were included in this review, including case series and reports, clinical trials, and reviews. For purposes of presentation, drug-inducing myopathies have been separated into discrete categories, including: rheumatologic and immunosuppressive, anti-infectious, cardiovascular, gastrointestinal, neurologic, and anti-neoplastic drugs. Drugs that alter electrolyte concentrations and drugs of abuse are also discussed. Finally, myopathic phenomena that may occur in patients in the intensive care setting are considered.
Rheumatologic and Immunosuppressive Drugs
The most common drug-induced myopathies seen by rheumatologists are probably caused by corticosteroids. Although the use of high-dose intravenous corticosteroids can result in acute generalized weakness (acute quadriplegic myopathy, see below), the typical corticosteroid myopathy is characterized by the insidious onset of proximal muscle weakness with normal serum CK levels. Respiratory muscles can be affected as well (1); their involvement mimics therapy-resistant asthma. (2) Corticosteroid myopathy most typically develops with chronic use of high doses (equivalent of 30 mg of prednisone or more a day) but can occur with lower doses or within a few weeks. (3) Although a necrotizing myopathy has been reported, it is extremely rare. (4) Risks of developing steroid myopathy increase with cumulative dose or duration, as well as multiple doses per day. Corticosteroid myopathy is more common among females than males, and is increased with the use of fluorinated agents (triamcinolone, betamethasone, and dexamethasone). (5,6) An alternate-day dosing schedule reduces the risk of occurrence.
An EMG is normal and of little help in the diagnosis of steroid-induced myopathy. (7) Muscle histology appears normal or shows nonspecific type 2 (fast-twitch glycolytic type 2B) fiber atrophy. (3,8) Histochemical staining with oil red O may reveal increased lipid in type 1 fibers, and electron microscopy may show mild mitochondrial abnormalities. How corticosteroids induce myopathy is unclear. Hypotheses proposed include a catabolic effect on protein synthesis, increased protein degradation, altered carbohydrate or mitochondrial metabolism, or reduced sarcolemmal excitability. (9,10) Furthermore, corticosteroid-induced hypokalemia may also be a factor. (11)
Treatment of corticosteroid myopathy involves discontinuation of the offending agent or reduction to a physiologic dose in those with presumed adrenal suppression. Exercise programs may also be beneficial. (12) Recovery may be observed within 24 hours in some cases, but may take more time, particularly if the usage has been chronic. (3,13) A diagnostic dilemma occurs when a patient with an inflammatory muscle disease (e.g., polymyositis) is treated with corticosteroids, seems to improve, and then regresses again. If this scenario is accompanied by rising serum CK values, EMG abnormalities, or edema on magnetic resonance imaging (MRI) of the affected muscles, then the myositis is probably flaring. However, the only way to definitively evaluate the problem is to either increase or decrease the corticosteroid dose and assess the clinical response. If the patient improves with a decrease in dosage, the diagnosis was likely steroid myopathy. The clinician must also be aware that overly rapid withdrawal of chronically used steroids may itself lead to weakness and fatigue, in part, as a consequence of hypoadrenalism.
Colchicine use is associated with a variety of neuromuscular complications, including generalized myopathy, painful neuromyopathy, rhabdomyolysis, and, rarely, clinical and electrophysiologic myotonia. (14-17) These complications may occur after months of therapy or be of rapid onset.15,18 Concomitant use of diuretics and the presence of chronic kidney disease, or either, increases the risk of myopathy, whereas concomitant use of an HMG CoA reductase in hibitor (statin) or cyclosporine increases the likelihood of rhabdomyolysis. (19-22)
In colchicine myopathy, serum CK levels are typically elevated (at times in the absence of symptoms), ranging from minimal increase to 100-times the upper limit of normal. EMG may show neuropathic changes in distal muscles, as well as generalized myopathic changes. Nerve conduction studies reveal prolonged motor and sensory latencies distally. (23) A vacuolar myopathy is observed on muscle histology. The vacuoles are autophagic and stain strongly for acid phosphatase. (23) Colchicine myopathy is believed to result from an inhibition of tubulin polymerization into microtubules, as well as alteration in the expression of dopaminergic receptors. (24) Colchicine "bodies" (clumps of chromatin in the nuclei of hepatocytes) have been seen on electron microscopy. (25) Findings of axonal neuropathy are typically present on nerve biopsy. Complete recovery of nerve and muscle function commonly occurs once the colchicine is discontinued. Although pain usually resolves within 3 weeks, full recovery may take up to 6 months.
Hydroxychloroquine and Chloroquine
These quinoline derivatives can cause similar reversible myopathies, although the chloroquine myopathy is generally more severe. (26-28) Quinoline (also known as 1-azanaphthalen) myopathies are painless and slowly progressive, with proximal muscle weakness that tends to be more severe in the lower extremities. An associated neuropathy is found in some cases, and cardiomyopathy has been reported. Symptoms can develop after 6 months to 10 years of treatment. (28) In addition, chloroquine can cause a myasthenia-like syndrome or myotonia. (29,30) Muscle involvement in response to these drugs, particularly chloroquine, may be more common than usually presumed and as high as 20%. (31,32) Serum CK values are usually elevated. EMG shows myopathic changes of increased insertional activity, with positive waves, fibrillations, and voluntary motor unit action potentials (MUAPs) that are polyphasic, with decreased amplitude and short duration.26 Acid phosphatase staining vacuoles are present on muscle histology. Electron microscopy reveals that the vacuoles contain concentric lamellar debris and curvilinear bodies. In cases of clinical myopathy, an anatomical-pathological tissue study, including an ultrastructural study, is mandatory to confirm the diagnosis. (31)
The mechanism of hydroxychloroquine and chloroquine myopathy is thought to relate to their amphiphilic nature. The presence of both hydrophobic and hydrophilic regions allows them to localize to and interact with anionic phospholipids in organelles and membranes. The drug-lipid complexes are resistant to lysosomal enzyme digestion and lead to the formation of autophagic vacuoles. Large autophagic vacuoles may not be visible on biopsy unless the patient has been treated with the drug for at least 6 months. (32,33) Furthermore, in an experimental chloroquine myopathy model, the administration of 50 mg/kg/day of chloroquine to rats for 8 weeks produced myopathy characterized by accumulation of similar autophagic vacuoles. (34)
After stopping treatment with these agents, most patients improved favorably, some over periods of up to 6 months. (35) Animal studies showed that administration of cysteine proteinase inhibitor, EST (epoxysuccinylleucylamido3-methylbutane ethyl ester), may improve chloroquine myopathy. (36) Hydroxychloroquine may also induce ciliary body muscle dysfunction, leading to impairment of visual accommodation. This problem presents early, after initiation of the agent, and typically resolves with continued use.
Cyclosporine and Tacrolimus
Cyclosporine and tacrolimus may cause generalized myalgias, cramps, and proximal muscle weakness. (37,38) These symptoms usually follow after several months of use, and resolve with lowering of the dose or discontinuing the medication. Some patients taking these agents develop rhabdomyolysis. (39,40) This severe complication is more likely if the patient is also taking either a lipid-lowering agent (statin or fibrate) or colchicine. (25) Serum CK levels are elevated. EMG changes include fibrillation potentials, sharp positive waves, and myotonic potentials. (41) Type 2 fibers atrophy, and vacuoles and necrosis may be seen with muscle histology. It is theorized that these agents destabilize lipophilic muscle membranes. It is important to keep in mind that the complications of these drugs are important, since it was reported recently that these agents have a role in the treatment of inflammatory muscle diseases, such as dermatomyositis and inclusion body myositis. (42)
Other Rheumatologic Agents
Up to 1.4% of patients taking D-penicillamine develop polymyositis or dermatomyositis. (43) Azathioprine has been linked very rarely to rhabdomyolysis. (44) Myokymia, or arrhythmic rippling of muscles (see later), is an unusual side effect of gold salt therapy. (45) According to a single case report, aspirin may also cause rhabdomyolysis. (46) Oral bisphosphonates may rarely induce severe muscle pain. (47)
Many of the agents used to treat HIV infection can cause myopathy. Myopathy is most common with zidovudine (azidothymidine, AZT), which causes progressive proximal muscle weakness, myalgias, and fatigue. (48-50) Similar presentations can occur with other nucleoside analog reverse transcriptase inhibitors, such as didanosine, lamivudine, and zalcitabine. (51-53) In reverse transcriptase inhibitor myopathy, serum CK levels are usually normal or only slightly elevated. EMG changes are primarily seen in proximal muscles and may include increased insertional activity, with sustained runs of positive sharp waves and fibrillation potentials; complex repetitive discharges; and early recruitment of polyphasic MUAP of short duration and small amplitude. (54,55) However, these changes may be difficult to differentiate from those resulting from myopathies related to HIV infection itself, including noninflammatory necrotizing myopathy and HIV wasting syndrome. (55) Muscle biopsy in reverse transcriptase-myopathy shows evidence of a mitochondrial myopathy, with ragged-red fibers apparent on modified Gomori trichrome stain and cytochrome oxidase-negative fibers with histochemistry. (49,56) In addition, necrosis, microvacuoles, cytoplasmic bodies, and nemaline rods may be present. (49,50) Proposed mechanisms of this drug-induced myopathy include induction of oxidative stress, direct inhibition of mitochondrial bioenergetic machinery, mitochondrial depletion of L-carnitine, and induction of apoptosis. (57) The nucleotide analog reverse transcriptase inhibitors, tenofovir and ritonavir (both components of the highly active antiretroviral therapy agents), may also cause severe rhabdomyolysis. This complication is rare and is more likely in patients who are also taking a macrolide antibiotic or a statin. (58,59)
Antifungal and Antibacterial Agents
Ketoconazole and itraconazole use can cause myopathy or rhabdomyolysis when used with a statin. (60,61) Rifampin may cause a severe proximal myopathy with normal serum CK levels, normal EMG, and type 2 fibers atrophy on biopsy. (62) Myalgias can occur, associated with tendinopathy and arthralgia, with the use of fluoroquinolones. (63) These agents can also trigger malignant hyperthermia. (64) In rare cases, nalidixic acid can cause myopathy characterized by proximal muscle weakness. It develops shortly after initiation of drug treatment and resolves after withdrawal of the agent. (65)
The most common drug-induced myopathies encountered today are caused by lipid-lowering agents, including 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), fibric acid derivatives (fibrates), and niacin. Ezetimibe may also cause myopathy in individual cases. (66,67) Although the risk of developing myotoxicity from one of these agents is low for the individual patient, (68) the large number of patients taking these agents renders this a common problem. In many clinical trials, statin-induced myopathy has been defined as muscle pain, tenderness, and weakness, with elevated serum CK levels greater than 10-times the upper limit of normal. According to this definition, the incidence of myopathy in patients treated with statins is 11 per 100,000 person-year. The incidence of rhabdomyolysis is 3.4 per 100,000 personyear. (69) This number is 10-times greater when fibrates are used in combination with statins. Clinical data shows that the incidence is higher with lovastatin, simvastatin, and atorvastatin, which are metabolized by cytochrome P450 (see below), compared to pravastatin and fluvastatin. In vitro data suggests that the rank order of cytotoxicity is starts with pravastatin as least toxic, followed by rosuvastatin, pitavastatin, lovastatin, atrovastatin, fluvastatin, simvastatin, and cerivastatin as the most cytotoxic statin. (70)
Clinically, some patients develop myopathic symptoms with statin exposure, despite normal CK levels, while others have persistently elevated CK levels without muscle symptoms. (71-73) Interestingly, in some studies, isolated CK elevations (less than 10-times the upper limit of normal) occur with similar frequency on the placebo- and statin-treated arms.69 Symptoms of statin-induced myopathy include any combination of myalgias, muscle tenderness, or weakness. Patients describe an aching or cramping sensation in their muscles, particularly those of the proximal limbs and the trunk. (74) Nocturnal leg cramps and tendon pain may be prominent features. (75,76) Statin-attributed tendinopathy is rare, considering the huge number of statin prescriptions. Recent work characterized tendon manifestations in 96 statin-treated patients; 65% of the patients exhibited tendinitis, while 35% had tendon rupture. (77) Tendinopathy more often occurred within the first year after statin initiation. Tendon manifestations were related to atorvastatin, simvastatin, pravastatin, fluvastatin, and rosuvastatin. In this work, as well as in other reported cases, rechallenge produced tendinopathy. (78,79) Repair of an injured tendon requires degradation and remodeling of the extracellular matrix through matrix metalloproteinases (MMPs). Statins inhibit MMPs, and it is, therefore, hypothesized that these drugs may increase the risk of tendon rupture by altering MMP activity. (78,79)
Although muscle weakness in statin-associated myopathy is usually proximal, distal muscles can occasionally be involved. (71) Vigorous exercise is poorly tolerated by many statin users and can aggravate statin-induced myotoxicity. (80,81) Myopathy due to lipid-lowering agents can develop at any time, but the average time to onset is about six months. The mean duration for symptoms to resolve after discontinuing the therapy is two months. (72) Although muscle symptoms generally resolve after cessation of statin therapy, they may persist. (80,81) In some patients, such persistent symptoms may be related to previously unrecognized neuromuscular disorders, including inflammatory myopathies (81-83); hypothyroidism (84); metabolic myopathies (myophosphorylase deficiency, acid maltase deficiency, and mitochondrial myopathy) (80,85,86); myotonic dystrophy (85); spinal muscular atrophy85; or susceptibility to malignant hyperthermia. (87) Statin-associated myopathy can be distinguished from polymyalgia rheumatica, since the erythrocyte sedimentation rate is not elevated in the former. The most severe form of myotoxicity in patients taking statins is rhabdomyolysis, which may result in acute renal failure, disseminated intravascular coagulation, and death.88,89 There is no specific imaging study to support the diagnosis. A recent case report described the findings on 18FDG-PET [F-18-fluoro-2-deoxy-D-glucose positron emission tomography] imaging in a patient with statin-induced rhabdomyolysis. There was intense patchy tracer uptake in the skeletal muscles, particularly in the upper extremities, around the pelvic girdle, and in intercostal muscles. (90) It is unclear whether there is tracer uptake in patients with less severe statin-induced myopathy.
Muscle tissue from patients with lipid-lowering drug-associated myopathy is often normal by light microscopy. (91) However, biopsies may show changes indicative of mitochondrial dysfunction, including ragged red fibers, and fibers with absent cytochrome C oxidase activity by immunohistochemistry. (93) Lipid-filled vacuoles (71,92) and fibers atrophy may also be seen. (80)
The risk of myotoxicity due to lipid-lowering agents is determined primarily by factors that lead to higher drug levels in the blood or tissues. These include drug dose, propensity for drug-to-drug interactions, or renal and hepatic dysfunction. (73,93-98) Myotoxicity is more common when two classes of lipid-lowering drugs are administered simultaneously. Gemfibrozil impairs statin elimination through inhibition of statin glucuronidation, whereas fenofibrate does not have that effect. (96) The concomitant use of niacin with a statin is rarely associated with rhabdomyolysis. (97)
Most statins are metabolized primarily by the hepatic microsomal cytochrome (CY) P-450 system. Exceptions include pravastatin, which is metabolized in the hepatic cytosol, and rosuvastatin, excreted largely in its parent form. Co-administration of a statin and another drug that is metabolized by the same CYP-450 isozyme can lead to a clinically significant drug-to-drug interaction. In addition, drugs that are CYP-3A4 substrates also increase the risk of statin-induced myotoxicity. These include cyclosporine, erythromycin and other macrolide antibiotics, azole antifungals, diltiazem (and other nondihydropyridine calcium channel blockers), ritonavir (and other protease inhibitors), nefazodone, and grapefruit juice. Fluvastatin is a CYP-2C9 substrate, and its hepatic metabolism can be impaired by coadministration of other CYP-2C9 substrates, such as diclofenac, warfarin, and tolbutamide.
The mechanisms that may contribute to the myotoxicities of lipid-lowering agents are not completely understood. Most of the mechanisms proposed involve membrane alterations or mitochondrial abnormalities. Inhibition of HMG-CoA reductase may impair synthesis of transfer RNAs, glycoproteins, the electron transport chain proteins heme A, and ubiquinone (coenzyme Q10), as well as small G-proteins involved in cell signaling and attenuation of apoptosis. (99) Levels of ubiquinone are modestly decreased in the affected muscle in some patients. (80,100) An important work suggested that the muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. (101) Respiratory chain and citrate synthase enzyme activities are decreased, and some patients have abnormalities in muscle carnitine levels. (80,102) Cardiopulmonary exercise testing may show decreased anaerobic thresholds and increased fasting respiratory exchange ratios (RER), compared to normal volunteers. (81) Rippling muscle disease is a rare disorder involving muscle contractions, which produces a visible rippling affect. A report that simvastatin can trigger rippling muscle disease suggests statins may have muscle side effects other than those traditionally reported.103 Thyroid function tests and genetic tests for the most common metabolic myopathies (myophosphorylase, carnitine palmitoyltransferase II, and myoadenylate), may identify individuals at higher risk of developing myotoxicity from lipid-lowering agents. (80)
If a patient taking a lipid-lowering drug develops intolerable muscle symptoms or a marked CK elevation, the drug should be discontinued. Hospitalization is required for significant rhabdomyolysis. For less severe symptoms or for CK elevations that are under 10-times the upper limit of normal, management recommendations vary. (104,105) One can continue the agent with close monitoring of the patient's symptoms and CK levels, or lower the dose. Another option is to discontinue the drug until the symptoms resolve, and then either reinstitute the drug at the same or a lower dose, or switch to a different statin or class of lipid-lowering drug therapy. Ubiquinone (coenzyme Q10) supplementation may be helpful in some, but not all, cases. (106) Recently, the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) collaborative group carried out a genomewide association study in order to identify markers of statin-associate myopathy. They found a strong association of myopathy with single-nucleotide polymorphism located within the SLCO1B1 gene. This gene encodes anion-transporting protein that has been shown to regulate hepatic uptake of statins. (107)
The adrenergic blocker labetalol may be associated with either acute or insidious onset of myalgias or proximal muscle weakness. (108) Serum CK levels are elevated, and muscle histology may be unremarkable or demonstrate necrotic and regenerating fibers.
Amiodarone can cause significant proximal and distal muscle weakness that tends to be more severe in the lower extremities. Distal sensory loss, tremor, and ataxia can also develop. (109) These toxicities are rare but occur more commonly in patients with chronic kidney disease. Serum CK levels are increased in amiodarone myopathy. EMG reveals fibrillation potentials, positive sharp waves, and early recruitment of myopathic MUAP in proximal muscles. In contrast, changes in distal muscles include polyphasic MUAP of large amplitude and long duration, with decreased recruitment when neuropathy is present. (110) Neurophysiologic testing reveals decreased amplitudes of CMAP (compound motor action potential) and SNAP (sensory nerve action potential) in the lower extremities. Autophagic vacuoles containing myeloid inclusions and debris are found on histology and electron microscopy. Amiodarone-induced myopathy gradually resolves after therapy is discontinued. However, amiodarone treatment can also lead to myopathy by causing hypothyroidism. The latter would respond to thyroid replacement therapy. Caution is required when amiodarone is administrated along with statins. (111)
Procainamide treatment can be accompanied by myalgias and proximal muscle weakness. (43,112) These symptoms usually develop in the context of the drug-induced lupus syndrome. Serum CK levels are increased and EMG changes are consistent with an inflammatory myopathy. Muscle histology of procainamide toxicity resembles that of idiopathic inflammatory myopathy. This includes necrotic fibers and perivascular inflammation. Thus, procainamide myopathy should be suspected in cases of idiopathic inflammatory myopathy when history suggests treatment with this agent.
Omeprazole use is rarely associated with a neuromyopathy that mainly affects the lower extremities. Features include proximal muscle weakness, myalgias, paresthesias, and sensory loss in a stocking distribution. (113) Levels of serum CK are increased. EMG and nerve conduction studies are consistent with an axonal sensorimotor neuropathy. Type 2 fiber atrophy is the typical histologic alteration. Patients taking cimetidine may rarely experience myalgias, cramps, myokymia, or weakness. A few reports have linked the use of cimetidine or ranitidine to polymyositis. (114,115) Interferon-[alpha] is used in the management of viral hepatitis. Whether this agent causes myalgias and fatigue is not clear, as these are common complaints in patients with hepatitis B and hepatitis C. Interferon-[alpha], however, can cause autoimmune disorders, including myositis and myasthenia gravis. (116,117)
Myalgias and weakness may accompany hypersensitivity reactions to phenytoin and are characterized by fever, rash, and lymphadenopathy. (118,119) Serum CK levels are elevated. Muscle histology reveals degenerating and regenerating fibers. Patients improve with discontinuation of the drug and may also benefit from corticosteroids. The anti-seizure medication valproic acid can induce a limb-girdle weakness with myopathic EMG changes by causing carnitine deficiency. (120) Valproic acid also has been recognized to trigger myopathic symptoms and rhabdomyolysis in individuals with lipid storage disorders or carnitine palmitoyltransferase deficiency. (121,122) The use of the levodopa to treat Parkinson's disease has been associated with myositis. (123)
Although the most common toxic effect of vincristine is a peripheral axonal neuropathy, proximal muscle weakness and myalgias can also occur. (123) Nerve conduction and EMG studies reveal neuropathic changes. The primary abnormality on muscle histology and histochemistry is denervation atrophy, but areas of segmental necrosis occasionally can be seen. Vincristine toxicity is ascribed to the drug's primary mechanism of action, specifically, disruption of microtubule polymerization, resulting in alterations of lysosomal function.
The kinase inhibitor imatinib mesylate, used to treat chronic myelogenous leukemia, causes myalgias in up to 50% of patients. (124) There is one report of polymyositis developing in a patient receiving this drug. (124) The myositis resolved after imatinib discontinuation and a course of corticosteroids. The investigators speculated that this was the result of an autoimmune response, since circulating antibodies directed against CML28 were found in the patient. CML28 is a component of a multiprotein complex, also known as an exosome, involved in RNA processing. Curiously, antibodies directed against this antigen and other exosome proteins (PM-Scl 100 and PM-Scl 70) are found in many patients with idiopathic inflammatory myopathies. Cardiotoxicity and dermatomyositis-like disease were reported as well. (125)
An inflammatory myopathy has been attributed to the use of leuprolide acetate in the treatment of prostate cancer. (126) Rare cases of rhabdomyolysis have been reported in patients taking 5-azacytidine, cytabrine, and the combination of cyclophosphamide and mitoxantrone. (127,128)
Drugs That Change Electrolyte Concentrations
Most drug-induced myopathies are due to direct effects on cellular structures or alterations in muscle fiber metabolism. However, use of a variety of drugs may be associated with myalgias, cramps, or weakness, resulting from effects they have on the concentrations of sodium, potassium, calcium, magnesium, or phosphorous. (129) Normal muscle contraction and relaxation are energy-dependent processes that require the activities of a sodium-potassium ATPase on the sarcolemma (a calcium-dependent ATPase in the sarcoplasmic reticulum) and a magnesium-dependent ATPase in the sarcoplasm. Accordingly, any drug that raises or lowers the concentration of these electrolytes can interfere with the orderly function of the tissue, causing myopathy. Clinically, this form of myopathy is most commonly caused by drugs that induce hypokalemia (Table 3). Muscle histology may show vacuoles in hypokalemic myopathy, regardless of the offending drug. Severe electrolyte imbalance also may cause rhabdomyolysis. (129,130)
Addictive Or Illicit Drugs
Excessive use of alcohol, narcotics, or illicit drugs can cause muscle injury by several mechanisms: direct toxic injury to the muscle fibers, ischemia from vasoconstriction, compression injury that occurs during coma, or inflammatory reactions to substances (drug or contaminant) injected intramuscularly.
Alcoholic myopathies may be classified into several types, although the different forms may coexist or overlap. These conditions include: 1) acute necrotizing myopathy, 2) acute hypokalemic myopathy, and 3) chronic alcoholic myopathy. (131-134) Alcohol use can also be associated with asymptomatic hyper-CK-emia. Recovery may occur if the offending agent is discontinued and the patient receives appropriate supportive care and nutrition.
Acute necrotizing myopathy is typically seen in chronic alcohol users after consuming large quantities in a short period of time (binge drinking). Such individuals develop acute muscle pain with swelling and tenderness. Serum CK levels are markedly elevated and myoglobinuria can precipitate renal failure. Extensive fiber necrosis, intracellular edema, and tubular aggregates are seen on muscle histology. In contrast, patients with alcohol-induced hypokalemic myopathy develop painless, generalized weakness (sometimes flaccid paralysis). There is no cramping or muscle tenderness on exam. Serum CK levels are elevated and serum potassium levels may be less than 2.0 mEq/L. As with other hypokalemic states, vacuoles are seen on biopsy.
Chronic alcoholic myopathy causes weakness with a proximal distribution of insidious onset or generalized muscle wasting, but no complaints of myalgias. The patients themselves may be unaware of any weakness. Serum CK levels are variable; typically, they are mildly elevated and return to normal with abstinence. Although degenerating and regenerating fibers may be observed on muscle histology, fiber atrophy, especially of type 2B fibers, is the more common finding.
Cocaine, amphetamines, phencyclidine, marijuana, and heroin can all cause muscle damage, via either vasoconstrictive ischemia; compression injuries that occur with coma, agitation, and seizures; or direct toxic effects. (33,135-137) Frequently, these present as acute syndromes with rhabdomyolysis (see below). However, cocaine use can also lead to asymptomatic hyper-CK-emia that persists for 1 to 2 months after use. Local necrosis or focal myositis may result from the intramuscular injection of these substances or foreign materials used to "cut" the agents. (138) Toluene is a component of some substances that are inhaled ("huffed"). Its abuse can lead to profound generalized weakness and coma, associated with elevated serum CK levels, hypokalemia, hypophosphatemia, and hypocalcemia, and a profound metabolic acidosis. (139)
Possible Drug-Related Myopathies in the Intensive Care Unit
A number of acute muscle disorders may be seen in patients on intensive care units, with some ascribable in whole or part to medications.
Acute Quadriplegic Myopathy
The first case of acute quadriplegic myopathy was described, in 1977, in a mechanically ventilated patient with status asthmaticus, who received neuromuscular blockade and high doses of intravenous corticosteroids. (140) Subsequently, the terms "critical care illness myopathy," "acute illness myopathy," and "myopathies associated with thick filament (myosin) loss" have also been applied to this syndrome. (33,141-144) It is often seen with coexisting critical care polyneuropathy. (145) Organ transplant patients who have received high-dose corticosteroids may be at increased risk. (146) Although most patients who have developed this syndrome have received high doses of intravenous corticosteroids with or without neuromuscular blocking agents, it has also been reported in patients with sepsis or multi-organ failure who had received neither agent. (147-149)
In acute quadriplegic myopathy, generalized muscle weakness, typically, develops over several days. Ophthalmoplegia is rarely associated. (150) The diagnosis should be suspected in candidate patients who cannot be weaned from a ventilator support. Sensory examination is normal, but deep tendon reflexes are diminished or absent. Serum CK values are modestly elevated in about half the patients, and EMGs are abnormal. (144,151) Nerve conduction studies in patients with acute quadriplegic myopathy reveal a dramatic decrease in compound muscle action potential amplitude in the setting of normal sensory potentials. EMG has demonstrated diffuse fibrillation, short duration, polyphasic, and often low amplitude motor unit potentials, which recruited in a myopathic fashion. (144) Affected muscles are also electrically inexcitable. (151) Changes in muscle histology include type 2 fiber atrophy, generalized atrophy, and necrosis. (142,144,145,148,149) Diminished myosin filaments are observed on electron microscopy or with histochemical staining. This change is attributed to the increased expression of calpain, a calcium-activated protease. (149)
Treatment involves discontinuing the corticosteroids and neuromuscular blocking agents, if possible, and resolving the underlying condition. Physical therapy is useful in preventing contractures. Although acute quadriplegic myopathy is associated with a 30% mortality rate, those that recover gradually regain strength over a period of several months.
Malignant hyperthermia is characterized by high fever with intense muscle rigidity and myoglobinuria, and it is often associated with cardiac arrhythmias. The vast majority of cases occur in patients after receiving either depolarizing muscle relaxants, such as succinylcholine, or inhaled an esthetics, such as halothane. Caffeine, tricyclic antidepressants, monamine-oxidase inhibitors, and fluoroquinolones, as well as exercise and stress, have been reported to trigger attacks. (64,152,153) Individuals with a muscular dystrophy may have a greater risk of developing this condition. (154) Malignant hyperthermia occurs in 0.0005% to 0.5% of patients who receive anesthesia. Over half of the individuals who developed malignant hyperthermia had previously undergone anesthesia without a problem. (155)
Serum CK levels may be initially normal or mildly elevated in asymptomatic, susceptible individuals, but rise dramatically during attacks. Myoglobinuria, hyperkalemia, and lactic acidosis all develop. Malignant hyperthermia has an autosomal dominant inheritance and can result from several different mutations, including mutations in the genes for the ryanodine receptor, the dihydropyridine-sensitive L-type voltage-dependent calcium channel gene, and the calcium channel subunit CACNA 2. (156,157) These mutations allow excessive calcium release from the sarcoplasmic reticulum into the sarcoplasm, resulting in intense muscle contraction. Why this release is provoked by certain medications is unknown.
Summary and Conclusions
The clinical spectrum of drug-induced myopathies is wide and ranges from asymptomatic elevations in serum CK levels to severe rhabdomyolysis. While some drugs commonly cause muscle problems, virtually any medication may cause muscle symptoms on a rare or idiopathic basis. Biopsy and EMG results may vary, ranging from normal to severe disruption, and, in addition, may not always correlate perfectly well with the degree of symptomatology. In most cases, the pathophysiology of the affected muscle is poorly understood, but can range from atrophic to frankly inflammatory. Overall, our understanding of muscle disease, whether drug-induced or otherwise, is clearly in its infancy. Nonetheless, the frequency with which muscle symptoms or pathology may occur makes it important for clinicians to be aware of potential myopathy resulting from pharmacologic therapies. Although no review can be exhaustive, we have attempted to address the most commonly used agents associated with muscle disease.
Careful monitoring of rheumatic and other conditions is important when prescribing therapies with potential for muscle toxicity. A drug-induced myopathy should be suspected when no other recognizable cause of myopathy is available and when there is no history of muscle symptoms prior to initiating the therapy. Although in many cases the myopathy will be seen to occur shortly after starting the agent, in some cases, a myopathy may develop chronically or come on acutely after long-term use of a particular therapy. When a drug-related myopathy is suspected, the possible offending agent should be withdrawn or reduced if at all possible. Subsidence of symptoms or pathology, or both, upon discontinuation of the agent supports a diagnosis of drug-induced myopathy. Unfortunately, some patients with presumed drug-induced myopathies experience persistence of difficulties even after the agent is discontinued. Nonetheless, early diagnosis and drug discontinuation improves the chances of a rapid and complete resolution.
None of the authors have a financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony.
(1.) Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1958-64.
(2.) Yamaguchi M, Niimi A, Minakuchi M, et al. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol. 2007;99:371-4.
(3.) Kissil JT, Mendell JR. The endocrine myopathies. In: Rowland LP, DiMauro S, (eds): Handbook of Clinical Neurology. (vol 18). Amsterdam (Netherlands): Elsevier Science Publishers, 1992, pp. 527-551.
(4.) Hanson P, Dive A, Brucher JM, et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve. 1997;20:1371-80.
(5.) Dubois EL. Triamcinolone in the treatment of systemic lupus erythematosus. JAMA. 1958;167:1590-9.
(6.) Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histological, and cytologic observations. John Hopkins Med J. 1968;123:158-74.
(7.) Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. 1976;61:485-92.
(8.) Khaleeli AA, Edwards RHT, Gohil K, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endoctrinol. 1983;18:155-66.
(9.) Pacy PJ, Halliday D. Muscle protein synthesis in steroid-induced proximal myopathy: a case report. Muscle Nerve. 1989;12:378-81.
(10.) Oshima Y, Kuroda Y, Kunishige M, et al. Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle Nerve. 2004;30:49-54.
(11.) Powell RJ. Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Am J Gastroenterol. 1969;52:425-32.
(12.) Horber FF, Scheidegger JR, Grunwig BE, et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61:83-8.
(13.) Faludi G, Gotlieb J, Meyers J. Factors influencing the development of steroid-induced myopathies. Ann NY Acad Sci. 1966;138:62-72.
(14.) Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562-8.
(15.) Riggs JE, Schochet SS Jr, Gutmann L, et al. Chronic human colchicine neuropathy and myopathy. Arch Neurol. 1986;43:521-3.
(16.) Dawson TM, Starkebaum G. Colchicine induced rhabdomyolysis. J Rheumatol. 1997;24:2045-6.
(17.) Rutkove SB, De Girolami U, Preston DC, et al. Myotonia in colchicine myoneuropathy. Muscle Nerve. 1996;19:870-5.
(18.) Schiff D, Drislane FW. Rapid-onset colchicine myoneuropa thy. Arthritis Rheum. 1992;35:1535-6.
(19.) Chattopadhyay I, Shetty HMG, Routledge PA, et al. Colchicine induced rhabdomyolysis. Postgrad Med J. 2001;77:191-4.
(20.) Simkin P, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000;27:1334-7.
(21.) Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report. Neuro toxicology. 2006;27:1126-7.
(22.) Francis L, Bonilla E, Soforo E, et al. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol. 2008;27:129-31.
(23.) Kuncl RW, Cornblath DR, Avila O, et al. Electrodiagnosis of human colchicine myoneuropathy. Muscle Nerve. 1989;12:360-4.
(24.) Jiang Q, Yan Z, Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J Biol Chem. 2006;281:29391-400.
(25.) Sundov Z, Nincevic Z, Definis-Gojanovic M, et al. Fatal colchicine poisoning by accidental ingestion of meadow saffron-case report. Forensic Sci Int. 2004;149:253-6.
(26.) Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med. 1987;82:447-55.
(27.) Richards AJ. Hydroxychloroquine myopathy. J Rheumatol 1998;25:1642-3.
(28.) Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyo toxicity. J Rheumatol. 2000;27:2927-31.
(29.) Sghirlanzoni A, Mantegazza R, Mora M, et al. Chloroquine myopathy and myasthenia-like syndrome. Muscle Nerve. 1988;11:114-9.
(30.) Kwiecinski H. Myotonia induced by chemical agents. Crit Rev Toxicol. 1981;90:287-99.
(31.) Casado E, Gratacos J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65:385-90.
(32.) Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheum. 1995;34:166-70.
(33.) Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin. 2005;23:397-428.
(34.) Kimura N, Kumamoto T, Kawamura Y, et al. Expression of autophagy-associated genes in skeletal muscle: an experimental model of chloroquine-induced myopathy. Pathobiology. 2007;74:169-76.
(35.) Becerra-Cunat JL, Coll-Cantf J, Gelpf-Mantius E, et al. Chloroquine-induced myopathy and neuropathy: progressive tetraparesis with areflexia that simulates a polyradiculoneuropathy. Two case reports. Rev Neurol. 2003;36:523-6.
(36.) Sugita H, Higuchi I, Sano M, et al. Trial of a cysteine proteinase inhibitor, EST, in experimental chloroquine myopathy in rats. Muscle Nerve. 1987;10:516-23.
(37.) Grezard O, Lebranchu Y, Birmele B, et al. Cyclosporininduced muscular toxicity. Lancet. 1990;335:177.
(38.) Noppen M, Velkeniers B, Dierckx R, et al. Cyclosporine and myopathy. Ann Intern Med. 1987;107:945-6.
(39.) Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988;318:46-7.
(40.) Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894-6.
(41.) Costigan DA. Acquired myotonia, weakness and vacuolar myopathy secondary to cyclosporine. Muscle Nerve. 1989;12:761.
(42.) Martfn Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc). 2006;127:697-701.
(43.) Takahashi K, Ogita T, Okudaira H, et al. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum. 1986;29:560-4.
(44.) Compton MR, Crosby DL. Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol. 1996;132:1254-5.
(45.) Caldron PH, Wilbourn AJ, Bravo EE, et al. Gold myokymia syndrome. A rare toxic manifestation of chrysotherapy. Cleve Clin J Med. 1987;54:225-8.
(46.) Leventhal LJ, Kuritsky L, Ginsburg R, et al. Salicylate-induced rhabdomyolysis. Am J Emerg Med. 1989;7:409-10.
(47.) Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;164:346-7.
(48.) Bessen LJ, Greene JB, Louie E, et al. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N Engl J Med. 1988;318:708.
(49.) Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Eng J Med. 1990;322:1098-105.
(50.) Grau JM, Masanes F, Pedrol E, et al. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol. 1993;34:206-11.
(51.) Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci. 1997;149:19-25.
(52.) Pedrol E, Masanes F, Fernandez-Sola J, et al. Lack of muscle toxicity with didansosine (ddI). Clinical and experimental Studies. J Neurol Sci. 1996;138:42-8.
(53.) Simpson DM, Katzenstein DA, Hughes MD, et al. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS. 1998;12:2425-32.
(54.) Simpson DM, Bender AN. Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann Neurol. 1988;24:79-84.
(55.) Simpson DM, Citak KA, Godfrey E, et al. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology. 1993;43:971-6.
(56.) Cote HCF, Brumme ZL, Craib KJP, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV infected patients. N Engl J Med. 2002;346:811-20.
(57.) Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology. 2008;82:83-8.
(58.) Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect. 2003;47:262-3.
(59.) Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of carithromycin, atorvastatin, lopinavir/ ritanovir in a patient with HIV. AIDS Patient Care STDS. 2003;17:207-10.
(60.) Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol. 1999;22:295-7.
(61.) Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333:664-5.
(62.) Jenkins P, Emerson PA. Myopathy induced by rifampicin. Br Med J. 1981;283:105-6.
(63.) Guis S, Bendahan D, Kozak-Ribbens G, et al. Investigation of fluoroquinolone-induced myalgia using magnetic resonance spectroscopy and in vitro contracture tests. Arthritis Rheum. 2002;46:774-8.
(64.) Guis S, Jouglard J, Kozak-Ribbens G, et al. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. J Rheum. 2001;28:1405-6.
(65.) Mor A, Pillinger MH, Wortmann RL, et al. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum. 2008;38:249-64.
(66.) Havranek JM, Wolfsen AR, Warnke GA, et al. Monotherapy with ezetimibe causing myopathy. Am J Med. 2006;119:285-6.
(67.) Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol. 2006;22:141-4.
(68.) Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35.
(69.) Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52-60.
(70.) Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 2008;82:969-75.
(71.) Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-5.
(72.) Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671-6.
(73.) Baker SK, Tarnopolsky MA. Statin-associated neuromyotox icity. Drugs Today (Barc). 2005;41:267-93.
(74.) Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40:163-71.
(75.) Bennett WE, Drake AJ 3rd, Shakir K. Reversible myopathy after statin therapy in patients with normal creatine kinase levels. Ann Intern Med. 2003;138:436-7.
(76.) Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17:459-65.
(77.) Marie I, Delafenetre H, Massy N, et al. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum. 2008;59:367-72.
(78.) Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol. 2007;100:152-3.
(79.) Movahed MR, Samsamsharaiat SA. Reproducible tendinitislike symptoms related to statin therapy. J Clin Rheumatol. 2006;12:320-1.
(80.) Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153-62.
(81.) Phillips PS, Phillips CT, Sullivan MJ, et al. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004;177:183-8.
(82.) Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne. 2004;25:294-8.
(83.) Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004;30:803-7.
(84.) Rando LP, Cording SA, Newnham HH. Successful reintroduction of statin therapy after myositis: was there another cause? Med J Aust. 2004;180:472-3.
(85.) Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166:1519-24.
(86.) Diaczok BJ, Shali R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. South Med J. 2003;96:318-20.
(87.) Guis S, Figarella-Branger D, Mattei JP, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum. 2006;55:551-7.
(88.) Hazin R, Abuzetun JY, Suker M, et al. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc. 2008;100:444-6.
(89.) Bays H. Statin safety: an overview and assessment of the data--2005. Am J Cardiol. 2006;97:6-26.
(90.) Sheehy N, Israel DA. Findings on (18)FDG-PET imaging in statin-induced rhabdomyolysis. Clin Radiol. 2007;62:1012-4.
(91.) Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62:1709-12.
(92.) Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol. 2004;36:85-9.
(93.) Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002;105:2341-6.
(94.) Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-90.
(95.) Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417-26.
(96.) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate plus statin versus gemfibrozil plus any statin. Am J Cardiol. 2005;95:120-2.
(97.) Shek A, Ferrill JM. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-17.
(98.) Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMGCoA reductase inhibitors. Ann Pharmacother. 2001;35:1096
(99.) Flint OP, Masters BA, Gregg RE, et al. HMG-CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145:99-110.
(100.) Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitcochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxical Appl Pharmacol. 2004;194:10-23.
(101.) Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007;117:3940-51.
(102.) Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-8.
(103.) Campbell WW. Statin myopathy: the iceberg or its tip? Muscle Nerve. 2006;34:387-90.
(104.) Seehusen DA, Asplund CA, Johnson DR, et al. Primary evaluation and management of statin therapy complications. South Med J. 2006;99:250-6.
(105.) Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400-9.
(106.) Kelly P, Vasu S, Gelato M, et al. Coenzyme Q10 improves myopathic pain in statin treated patients. J Am Coll Cardiol. 2005;45:3.
(107.) Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy--a genomicwide study. N Engl J Med. 2008;359:789-99.
(108.) Willis JK, Tilton AH, Harkin JC, et al. Reversible myopathy due to labetalol. Pediatr Neurol. 1990;6:275-6.
(109.) Fernando Roth R, Itabashi H, Louie J, et al. Amiodarone toxicity: myopathy and neuropathy. Am Heart J. 1990;119:1223-5.
(110.) Meier C, Kauer B, Muller U, et al. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol. 1979;220:231-9.
(111.) Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm. 2007;64:1818-21.
(112.) Lewis CA, Boheimer N, Rose P, Jackson G. Myopathy after short term administration of procainamide. Br Med J (Clin Res Ed). 1986 Mar;292:593-4.
(113.) Faucheux JM, Tournebize P, Viguier A, et al. Neuromyopathy secondary to omeprazole treatment. Muscle Nerve. 1998;21:261-2.
(114.) Hawkins RA, Eckhoff PJ Jr, MacCarter DK, et al. Cimetidine and polymyositis. N Engl J Med. 1983;309:187-8.
(115.) Pelletier A, Ekert S, Hauw JJ, et al. Inflammatory myopathy during ranitidine therapy. J Rheumatol. 1993;20:1453-4.
(116.) Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol. 2000;17:64-9.
(117.) Hengstman GJ, Vogels OJ, ter Laak HJ, et al. Myositis during long-term interferon-alpha treatment. Neurology. 2000;54:2186.
(118.) Harney J, Glasberg MR. Myopathy and hypersensitivity to phenytoin. Neurology. 1983;33:790-1.
(119.) Tun NZ, Andermann F, Carpenter S, et al. Antiepileptic drug myopathy. Neurology. 1994;44:777-8.
(120.) Sangeeta P. Sodium valproate-induced skeletal myopathy. India J Pediatr. 2005;72:243-4.
(121.) Papadimitriou A, Seruidei S. Multiple AcylCoA dehyrogenase deficiency triggered by valproate. Neuromuscul Disord. 1991;1:247-52.
(122.) Kottlors M, Jaksch M, Ketelsen UP, et al. Valproic acid triggers acute rabdomyolysis in a carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord. 2001;11:757-9.
(123.) Wolf S, Goldberg LS, Verity MA. Neuromyopathy and periarteriolitis in patient receiving levodopa. Arch Intern Med. 1976;136:1055.
(124.) Srinivasan J, Wu C, Amato AA. Inflammatory myopathy associated with imitinab therapy. J Clin Neuromuscul Disord. 2004;5:119-21.
(125.) Kuwano Y, Asahina A, Watanabe R, et al. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. Int J Dermatol. 2006;45:1249-51.
(126.) Crayton H, Bohlmann T, Sufit R, et al. Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma. Clin Exp Rheumatol. 1991;9:935-8.
(127.) Koeffler HP, Haskell CM. Rhabdomyolysis as a complication of 5-azacytidine. Cancer Treat Rep. 1978;62:573-4.
(128.) Levy RJ, Sparano JA, Khan G. Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. Med Oncol. 1995;12:219-22.
(129.) Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med. 1982;72:521-55.
(130.) Knochel JP, Barcenas J, Cotton TJ, et al. Hypophosphatemia and rhabdomyolysis. J Clin Invest. 1978;62:1240-6.
(131.) Fernandez-Sola J, Junyent JM, Urbano-Marquez A. Alcoholic myopathies. Curr Opin Neurol. 1996;9:400-5.
(132.) Kahn LB, Meyer JS. Acute myopathy in chronic alcoholism: a study of 22 autopsy cases with ultrastructural observations. Am J Clin Path. 1970;53:516-30.
(133.) Martin JB, Craig JW, Eckel RE, et al. Hypokalemic myopathy in chronic alcoholism. Neurology. 1971;21:1160-8.
(134.) Sacanella E, Fernandez-Sola J, Cofan M, et al. Chronic alcoholic myopathy: diagnostic clues and relationship with other ethanol-related diseases. QJM. 1995;88:811-7.
(135.) Herzlich BC, Arsura EL, Pagala M, et al. Brief report: rhabdomyolysis related to cocaine abuse. Ann Intern Med. 1988;109:335-6.
(136.) Richter RW, Challenor YB, Pearson J, et al. Acute myoglobinuria associated with heroin addiction. JAMA. 1971;216:1172-6.
(137.) Cogen FC, Rigg G, Simmons JL, et al. Phencyclidine-associated acute rhabdomyolysis. Ann Intern Med. 1978;88:210-2.
(138.) Louis ED, Bodner RA, Challenor YB, et al. Focal myopathy induced by chronic intramuscular heroin injection. Muscle Nerve. 1994;17:550-2.
(139.) Cronk SL, Barkley DEH, Farrell MF. Respiratory arrest after solvent abuse. Br Med J (Clin Res Ed). 1985 Mar 23;290(6472):897-8.
(140.) MacFarlane IA, Rosenthal FD. Severe myopathy after status asthmaticus. Lancet. 1977;2:615.
(141.) Howard RS, Tan SV, Z'Graggen WJ. Weakness on the intensive care unit. Pract Neurol. 2008;8:280-95.
(142.) Gooch JL. AAEM case report #29: prolonged paralysis after neuromuscular blockade. Muscle Nerve. 1995;18:937-42.
(143.) Danon MJ, Carpenter S. Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve. 1991;14:1131-9.
(144.) Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical, electomyographic, and pathological aspects. Ann Neurol. 1996;40:645-54.
(145.) Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve. 1998;21:610-7.
(146.) Campellone JV, Lacomis D, Kramer DJ, et al. Acute myopathy after liver transplantation. Neurology. 1998;50:46-53.
(147.) Deconinck N, Van Parijs V, Beckers-Bleukx G, et al. Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord. 1998;8:186-92.
(148.) Gutmann L, Blumenthal D, Schochet SS. Acute type II myofiber atrophy in critical illness. Neurology. 1996;46:819-21.
(149.) Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-medicated proteolysis. Muscle Nerve. 1997;20:316-22.
(150.) Sitwell LD, Weinshenker BG, Monpetit V, et al. Complete ophthalmoplegia as a complication of acute corticosteroid-and pancuronium-associated myopathy. Neurology. 1991;41:921 2.
(151.) Rich MM, Teener JW, Raps EC, et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology. 1996;46:731-6.
(152.) Bertorini TE. Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin. 1997;15:649-71.
(153.) Nelson TE, Flewellen EH. Current concepts. The malignant hyperthermia syndrome. N Eng J Med. 1983;309:416-8.
(154.) Sethna RL, Rockoff MA, Worthen HM, et al. Anesthesiarelated complications in children with Duchenne muscular dystrophy. Anethesiology. 1988;68:462-5.
(155.) Griggs RC, Mendell JR, Miller RG. Myopathies of systemic disease. In: Evaluation and treatment of myopathies. Philadelphia: FA Davis, 1995, pp. 355-385.
(156.) Monnier N, Procaccio V, Stieglitz P, et al. Malignanthyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316-25.
(157.) Robinson RL, Monnier N, Wolz W, et al. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet. 1997;6:953-61.
Adam Mor, M.D., is a Resident in the Department of Medicine, New York University School of Medicine. Hal J. Mitnick, M.D., is Clinical Professor of Medicine, and Michael H. Pillinger, M.D., is Associate Professor of Medicine and Pharmacology, New York University School of Medicine, and from the Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York. Robert L. Wortmann, M.D., is Professor of Medicine, Section of Rheumatology, Dartmouth Medical School, Lebanon, New Hampshire.
Correspondence: Adam Mor, M.D., Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016; email@example.com.
Table 1 Drugs that Can Cause Rhabdomyolysis Direct toxic effects Colchicine Cyclosporine Succinylcholine Tacrolimus Toluene (inhaled) Metabolic effects Alcohol Aspirin 5-Azacytidine Azathioprine Cyclophosphamide Fibric acid derivatives (fibrates) Heroine HMG CoA reductase inhibitors (statins) Hypokalemic agents (see Table 3) Methadone Mitoxantrone Ritanovir Tenofovir Valproic acid Exercise, agitation, Amphetamines or seizures Cocaine Neuoleptic agents Phencylidine Ischemia Cocaine Table 2 Keyword Terms Used in Search of Drug-induced Myopathies * Adverse-Drug-Reaction Alcohol Amiodarone Amphetamines Azathioprine Cardiomyopathy Chloroquine Cocaine Colchicine Corticosteroids Cramps Creatine-Phosphokinase Cyclophosphamide Cytochrome-P450 Cyclosporine Drug-Induced Electromyography (EMG) Fibrate Heroin Highly-Active-Antiretroviral-Therapy HIV Hydroxychloroquine Hypokalemia Imatinib-Mesylate Itraconazole Ketoconazole Leuprolide Macrolides Metabolic-Myopathies Myopathy Muscle Myalgias Myoglobinuria Niacin Phenytoin Procainamide Quinolones Renal-Failure Rhabdomyolysis Rifampin Statin Tacrolimus Toxicity Valproic-Acid Vincristine Ubiquinone Zidovudine Weakness. * List is not exhaustive for study Table 3 Drugs That Can Cause Hypokalemia Alcohol Amphotericin B Cisplatin Corticosteroids Diuretics Glycyrrhizic acid (licorice) Laxatives Lithium Mineralocorticoids Parenteral nutrition Theophylline Toluene (inhaled)
|Gale Copyright:||Copyright 2009 Gale, Cengage Learning. All rights reserved.|